Neoepitope Vaccine with Intratumoral Oncolytic Virus for Glioblastoma
Official title: Project 1: Neoepitope Vaccine plus Intratumoral Oncolytic Virus for Glioblastoma
Funded at Brigham and Women's Hospital · NIH-11417400 · Data updated 2026-11-12
A personalized tumor vaccine combined with a targeted virus therapy is being tested to boost immune attack against glioblastoma in patients.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 3, 2020 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $572,180 |
| NIH project number | 2P01CA236749-06A1 |
| Project ID | NIH-11417400 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with glioblastoma who are eligible for personalized NeoVax vaccination and intratumoral virus therapy.
✕Less likely to help
Patients not eligible for personalized neoantigen vaccination or unable to receive intratumoral virus delivery may not benefit.
What this research studies
This project aims to use NeoVax, a vaccine tailored to each patient’s tumor, together with doses of an intratumoral oncolytic virus to spark a stronger immune response. By pairing a personalized vaccine with immune-boosting virus therapy and checkpoint blockade, the approach seeks broader and longer-lasting tumor control. The study builds on prior safety and immunogenicity data and plans to test whether the combination works better than either therapy alone. Participants would receive tumor-specific vaccines, intratumoral virus injections, and immune checkpoint inhibitors as part of a coordinated treatment plan.
Why it matters
Potential benefit: If successful, patients could experience stronger and more durable anti-tumor immunity against glioblastoma.
How similar studies have gone: Earlier NeoVax studies showed safety and immunogenicity, and combining vaccines with immune therapies is a promising strategy in brain tumors.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Reardon, David a — Brigham and Women's Hospital
- Study coordinator: Reardon, David a
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.